Abstract
Mounting evidence suggests that pregnant people have an elevated risk of severe COVID-19-related complications compared with their non-pregnant counterparts, underscoring the need for effective prevention and treatment strategies. However, despite progress in innovative and flexible trial designs during the COVID-19 pandemic, regressive policies excluding pregnant and breastfeeding people from biomedical research persist. Remdesivir, a broad-spectrum antiviral, was the first drug licensed for the treatment of COVID-19, based on data showing it reduced the time to recovery in hospitalized patients. Pregnant and breastfeeding people were specifically excluded from all clinical trials of remdesivir in COVID-19, but data are accumulating from post-marketing registries, compassionate use programmes and case series/reports. In this review we synthesize these data and highlight key knowledge gaps to help inform clinical decision-making about its use in pregnancy and lactation.
【초록키워드】 COVID-19, Treatment, Breastfeeding, clinical trial, Trial, Antiviral, knowledge, COVID-19 pandemic, lactation, Remdesivir, risk, hospitalized patients, Pregnancy, Time to recovery, compassionate use, Evidence, pregnant, Biomedical research, Treatment strategies, treatment of COVID-19, These data, help, effective, highlight, flexible, elevated, reduced, excluded, accumulating, COVID-19-related complication, Mounting, 【제목키워드】 COVID-19,